We are live on
!
Find out more
ITP
Iron Triangle Partners Portfolio holdings
AUM
$875M
1-Year Est. Return
49.85%
This Fund
S&P 500
This Quarter
Est. Return
+14.44%
1 Year Est. Return
+49.85%
3 Year Est. Return
+151.9%
5 Year Est. Return
+239.84%
10 Year Est. Return
–
AUM
$748M
AUM Growth
+$54.9M
(+7.9%)
Cap. Flow
-$10.4M
Cap. Flow
% of AUM
-1.39%
Top 10 Holdings %
Top 10 Hldgs %
68.09%
Holding
35
New
8
Increased
7
Reduced
6
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Universal Health Services
UHS
|
+$65.6M |
| 2 |
Boston Scientific
BSX
|
+$44.4M |
| 3 |
United Therapeutics
UTHR
|
+$44.3M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$39M |
| 5 |
Icon
ICLR
|
+$34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$64.2M |
| 2 |
UnitedHealth
UNH
|
+$37.8M |
| 3 |
Gilead Sciences
GILD
|
+$34.8M |
| 4 |
Evolent Health
EVH
|
+$32.5M |
| 5 |
Charles River Laboratories
CRL
|
+$26.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Icon
ICLR
$13B
| $87.6M | 11.71% |
350,000
+160,000
| +84% | +$34M |
|
|
2
Universal Health Services
UHS
$9.64B
| $74.2M | 9.91% |
+470,000
| New | +$65.6M |
|
3
AbbVie
ABBV
$454B
| $60.6M | 8.1% |
450,000
+130,000
| +41% | +$19.1M |
|
|
EXAS
4
DELISTED
Exact Sciences
EXAS
| $47M | 6.28% |
+500,000
| New | +$39M |
|
|
5
Boston Scientific
BSX
$67.6B
| $46M | 6.15% |
+850,000
| New | +$44.4M |
|
|
6
United Therapeutics
UTHR
$26.3B
| $44.1M | 5.9% |
+200,000
| New | +$44.3M |
|
7
Intuitive Surgical
ISRG
$128B
| $41M | 5.49% |
120,000
| – | – |
|
8
Acadia Healthcare
ACHC
$2.99B
| $40.1M | 5.36% |
503,447
-9,259
| -2% | -$669K |
|
9
Establishment Labs
ESTA
$2.71B
| $36.9M | 4.93% |
537,906
+112,906
| +27% | +$7.8M |
|
10
Pacific Biosciences
PACB
$422M
| $31.9M | 4.27% |
2,400,000
+100,000
| +4% | +$1.22M |
|
11
Cooper Companies
COO
$13.7B
| $28.8M | 3.84% |
300,000
-40,000
| -12% | -$3.75M |
|
12
Surgery Partners
SGRY
$1.98B
| $26.1M | 3.49% |
580,973
-234,579
| -29% | -$8.95M |
|
13
Align Technology
ALGN
$12B
| $23M | 3.07% |
+65,000
| New | +$20.7M |
|
14
Inspire Medical Systems
INSP
$1.47B
| $22.7M | 3.04% |
70,000
| – | – |
|
15
Glaukos
GKOS
$8.92B
| $22.1M | 2.95% |
+310,000
| New | +$17.8M |
|
16
10x Genomics
TXG
$5.83B
| $21.2M | 2.84% |
380,000
+30,000
| +9% | +$1.62M |
|
17
DexCom
DXCM
$28.3B
| $19.3M | 2.58% |
150,000
-190,000
| -56% | -$23M |
|
18
PUT
Neurocrine Biosciences
NBIX
$17.7B
| $18.5M | 2.47% |
+196,000
| New | +$19.2M |
|
19
Brookdale Senior Living
BKD
$3.69B
| $17.7M | 2.36% |
4,183,353
+1,483,353
| +55% | +$5.73M |
|
20
Transmedics
TMDX
$2.57B
| $15.1M | 2.02% |
+180,000
| New | +$13.8M |
|
|
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
| $12.2M | 1.63% |
464,935
+152,271
| +49% | +$4M |
|
22
908 Devices
MASS
$293M
| $6.17M | 0.83% |
900,000
-150,000
| -14% | -$1.21M |
|
|
OLK
23
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $5.9M | 0.79% |
314,795
-85,205
| -21% | -$1.76M |
|
|
24
Charles River Laboratories
CRL
$10.8B
| – | – |
-130,000
| Closed | -$26.2M |
|
|
25
Evolent Health
EVH
$429M
| – | – |
-1,000,402
| Closed | -$32.5M |
|
Similar funds
8KM
MFG
NP
GGI
WFAL
OBWP
TWM
AGC
Iron Triangle Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Iron Triangle Partners held 35 positions worth $748M, up 7.9% from $693M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Iron Triangle Partners's Q2 2023 filing shows 8 new, 7 increased, 6 reduced and 12 closed positions. Its largest new stake was Universal Health Services: 470,000 shares worth $74.2M. The largest sale was Sanofi, an estimated $64.2M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.
- Iron Triangle Partners's largest Q2 2023 buy was Universal Health Services: 470,000 shares worth $74.2M.
- Iron Triangle Partners added most to Icon in Q2 2023, an estimated $34M increase.
- Iron Triangle Partners's biggest Q2 2023 reduction was DexCom, cutting an estimated $23M.
- Iron Triangle Partners fully exited Sanofi in Q2 2023, selling an estimated $64.2M.
- Iron Triangle Partners's ten largest holdings make up 68% of its $748M portfolio in Q2 2023.
- Iron Triangle Partners opened 8 new positions and closed 12 in Q2 2023.
- Iron Triangle Partners's portfolio value rose 7.9% quarter-over-quarter to $748M.
Based on Iron Triangle Partners's 13F filing for Q2 2023, filed 14 Aug 2023.